Bishal Gyawali: A checklist to design and report cancer drug RCTs
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X about a recent paper he co-authored with colleagues published in The Lancet Oncology:
“Now Online!
CSO RCT Checklist.
Common Sense Oncology RCT team has just published in The Lancet Oncology a checklist to design and report cancer drug RCTs.
You know about the CONSORT checklist for RCTs but this CSO checklist is specifically for cancer drug RCTs and incorporates items such as crossover, censoring etc that affect interpretation of cancer drug RCTs.
We have checklist at the design phase of RCTs, and hope trialists/trial funders/sponsors/reviewers/IRBs etc use this checklist to ensure the trials are designed to accurately answer questions that matter to patients.
We also have a checklist at the reporting phase of RCTs and hope authors/reviewers/editors/journals/readers and other users of the publication (regulators, payors, physicians, patients, media, public) use this checklist to ensure that the interpretations are made correctly and accurately.
Super thankful to and proud of our Common Sense Oncology Project RCT team for getting this published. Real work now begins to get this implemented.”
Authors: Bishal Gyawali, Elizabeth Eisenhauer, Winette van der Graaf, Brooke Wilson, Ian Tannock et al.
More posts featuring Bishal Gyawali.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023